Abstracts Archive - Page 1130 of 2425 - ACR Meeting Abstracts

Abstract Number: 1881 • 2018 ACR/ARHP Annual Meeting
Discovery and Validation of Novel Disease Subsets in 806 Patients with Takayasu’s Arteritis across Four International Cohorts
Ruchika Goel¹, Katherine B. Gribbons², Kathleen Maksimowicz-McKinnon³, Gary S. Hoffman⁴, Sathish Kumar⁵, George Joseph⁶, Raheesh Ravindran⁷, Aswin Nair⁸, David Cuthbertson⁹, Simon Carette¹⁰, Nader A. Khalidi¹¹, Curry L. Koening¹², Carol Langford¹³, Carol A. McAlear¹⁴, Paul A. Monach¹⁵, Larry W. Moreland¹⁶, Christian Pagnoux¹⁷, Philip Seo¹⁸, Antoine G. Sreih¹⁹, Kenneth J. Warrington²⁰, Steven R. Ytterberg²⁰, Peter A. Merkel²¹, Debashish Danda²² and Peter C. Grayson², ¹Rheumatology, Christian Medical College, Vellore Tamilnadu, India, ²National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, ³Rheumatology, Henry Ford Hospital, Detroit, MI, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH, ⁵Child Health, Christian Medical College, Vellore, India, ⁶Cardiology, Christian Medical College, Vellore, India, ⁷Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India, ⁸Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India, ⁹Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ¹⁰Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Rheumatology, McMaster University, Hamilton, ON, Canada, ¹²Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹³Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁵Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁶Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁷Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹⁸Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²⁰Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ²¹University of Pennsylvania, Philadelphia, PA, ²²Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India
Background/Purpose: Takayasu’s arteritis (TAK) is characterized by variable patterns of damage throughout the large arteries. This study aimed to develop and validate a novel disease…
Abstract Number: 1882 • 2018 ACR/ARHP Annual Meeting
Characteristics and Treatment Outcomes of Takayasu Arteritis in a Nationwide, Retrospective Cohort Study in Japan
Haruhito A. Uchida¹, Yoshikazu Nakaoka², Hajime Yoshifuji³, Takahiko Sugihara⁴, Yoshiko Watanabe⁵, Masayoshi Harigai⁶, Yoshihiro Arimura⁷ and Mitsuaki Isobe⁸, ¹Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, ³Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ⁵First Department of Physiology, Kawasaki Medical School, Kurashiki, Japan, ⁶Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan, ⁷Kyorin University School of Medicine, First Department of Internal Medicine, Tokyo, Japan, ⁸Sakakibara Heart Institute, Tokyo, Japan
Background/Purpose: Takayasu arteritis (TAK) typically affects young women under 40 years old, whereas patients with onset age over 40 years are occasionally observed. It still…
Abstract Number: 1883 • 2018 ACR/ARHP Annual Meeting
Infections Are Associated With Increased Risk of Giant Cell Arteritis – a Population-Based Case-Control Study From Southern Sweden
Pavlos Stamatis¹, Aleksandra Turkiewicz², Martin Englund², Goran Jönsson³, Jan-Åke Nilsson⁴, Carl Turesson⁵ and Aladdin Mohammad⁶, ¹Clinical Sciences, Rheumatology Lund, Lund University, Lund, Sweden, ²Clinical Sciences Lund, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ³Clinical Sciences Lund, Department of Infection Medicine, Lund University, Lund, Sweden, ⁴Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁵Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁶Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: Previous studies have implicated infections as a risk factor for giant cell arteritis (GCA). The purpose of this study was to investigate the association…
Abstract Number: 1884 • 2018 ACR/ARHP Annual Meeting
Clinical Features and Outcome of Patients with Polyarteritis Nodosa – a Global Collaborative Study
Omer Karadag^1,2, Shunsuke Furuta³, Alojzija Hočevar⁴, Ummugulsum Gazel⁵, Seerapani Gopaluni⁶, Berkan Armagan¹, Matija Tomsic⁷, Fatma Alibaz-Oner⁸, Ihsan Ertenli¹, Seza Ozen¹ and David Jayne², ¹Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ²Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom, ³Chiba University Hospital, Chiba, Japan, ⁴Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁵Rheumatology, Marmara University faculty of Medicine, Istanbul, Turkey, ⁶Medicine, University of Cambridge, Cambridge, United Kingdom, ⁷Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁸Department of Rheumatology, Marmara University, Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Polyarteritis nodosa (PAN) is a rare subgroup of the primary systemic vasculitides. Furthermore, various subgroups of PAN have been described, such as hepatitis B…
Abstract Number: 1885 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger’s disease): A Multicenter Study of 224 Patients
Alexandre LE JONCOUR¹, Simon Soudet², Axelle Dupont³, Olivier Espitia⁴, Fabien Koskas⁵, Philippe Cluzel⁶, Pierre-Yves Hatron², Joseph Emmerich⁷, Patrice Cacoub¹, Matthieu Resche-Rigon³, Marc Lambert² and David Saadoun¹, ¹Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier Pitié, Paris, France, ²Département de Médecine Interne et Immunologie Clinique, CHU Lille, F-59000 Lille, France, Centre National de Référence des Maladies Autoimmunes et Systémiques Rares (Sclérodermie), France, Lille, France, ³3Service de Biostatistique et Information médicale, Hôpital Saint-Louis, APHP, Paris, France, Paris, France, ⁴Département de Médecine interne, CHU de Nantes, France, Nantes, France, ⁵Service de chirurgie vasculaire, Groupe Hospitalier Pitié-Salpétrière, Paris, France, Paris, France, ⁶Service d’Imagerie Cardiovasculaire, Institut de cardiologie, Groupe Hospitalier Pitié-Salpétrière, Paris, France, Paris, France, ⁷Department of Vascular Medicine and Cardiology, University Hospital Hotel Dieu, University Paris-Descartes, Paris, France, Paris, France
Background/Purpose: Data regarding long term outcome of patients with thromboangiitis obliterans (TAO) are lacking and most series come from India and Japan. We assess long-term…
Abstract Number: 1886 • 2018 ACR/ARHP Annual Meeting
Phenotypic Subgroups in IgG4-Related Disease – a Cluster Analysis
Zachary Wallace¹, Yuqing Zhang², Cory A. Perugino³, Raymond P. Naden⁴, Hyon K. Choi⁵ and John H. Stone⁶, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ³Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, ⁴New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, ⁵Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ⁶Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a multi-organ condition of uncertain etiology characterized by substantial morbidity if not diagnosed and treated promptly. Identifying IgG4-RD subgroups based…
Abstract Number: 1887 • 2018 ACR/ARHP Annual Meeting
Practice Variation in Prescriptions of Non-TNFi Biologics and Tofacitinib: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Gabriela Schmajuk^1,2, Michael Evans³, Julia Kay², Megan E. B. Clowse⁴, Esi Morgan⁵, Andreas Reimold⁶, Tracy Johansson⁷, Lindsay Lewis⁸ and Jinoos Yazdany⁹, ¹San Francisco VA Medical Center, San Francisco, CA, ²Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ³University of California - San Francisco, San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ⁵University of Cincinnati, Cincinnati, OH, ⁶Rheumatology, University of TX Southwestern Medical Center, Dallas, TX, ⁷Practice, Advocacy & Quality, American College of Rheumatology, Atlanta, GA, ⁸American College of Rheumatology, Atlanta, GA, ⁹University of California, San Francisco, San Francisco, CA
Background/Purpose: Biologic DMARDs and tofacitinib account for a large proportion of drug spending in the U.S. Although TNFi drugs have dominated sales, use of…
Abstract Number: 1888 • 2018 ACR/ARHP Annual Meeting
SLE Among the Leading Causes of Years of Potential Life Lost in Young Women: Population-Based Study, 2000-2015
Eric Yen and Ram R. Singh, UCLA, Los Angeles, CA
Background/Purpose: Ten-year survival of SLE has improved from <50% in the 1950s to ~95% in the 2000s. However, the relative and true disease burden for…
Abstract Number: 1889 • 2018 ACR/ARHP Annual Meeting
Patterns of Glucocorticoid Use and Provider-Level Variation in a Commercially Insured Incident Rheumatoid Arthritis Population
Beth Wallace^1,2,3, Paul Lin^2,4, Neil Kamdar^2,4, Mohamed Noureldin^2,3,5, Rodney Hayward^2,3,6, David A. Fox¹, Jeffrey R. Curtis⁷, Kenneth Saag⁸ and Akbar Waljee^2,3,9, ¹Department of Internal Medicine, Division of Rheumatology, Michigan Medicine, Ann Arbor, MI, ²University of Michigan Institute for Healthcare Policy and Innovation, Ann Arbor, MI, ³Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁴University of Michigan Medical School, Ann Arbor, MI, ⁵Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁶Department of Internal Medicine, Division of General Medicine, Michigan Medicine, Ann Arbor, MI, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama, Birmingham, AL, ⁹Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Glucocorticoids (GC) reduce RA-related disability and joint damage; RA guidelines endorse short term use during DMARD initiation and flares. Long-term high-dose GC exposure (>3…
Abstract Number: 1890 • 2018 ACR/ARHP Annual Meeting
Longitudinal Deep Learning on Electronic Health Record Data to Predict Future Rheumatoid Arthritis Disease Activity
Beau Norgeot¹, Benjamin Glicksberg², Dmytro Lituiev², Laura Trupin³, Milena Gianfrancesco³, Atul Butte⁴, Gabriela Schmajuk⁵ and Jinoos Yazdany⁶, ¹Institute for Computational Health Sciences, University of California San Francisco, San Francisco, CA, ²University of California San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, ⁵Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ⁶University of California, San Francisco, San Francisco, CA
Background/Purpose: Rheumatoid Arthritis (RA) is a complex systemic inflammatory disease with variable course that is difficult to precisely predict. Deep Learning (DL), a branch of…
Abstract Number: 1891 • 2018 ACR/ARHP Annual Meeting
Patterns of Biosimilar Use in the Rheumatology Informatics System for Effectiveness (RISE) Registry
Nick Bansback¹, Jeffrey R. Curtis², Jie Huang³, Lindsay Lewis⁴, Tracy Johansson⁴, Kaleb Michaud⁵ and Katherine P. Liao³, ¹St Paul's Hospital, Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Practice, Advocacy & Quality, American College of Rheumatology, Atlanta, GA, ⁵Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: In the U.S., the first biosimilar tumor necrosis inhibitor (TNFi) was approved in 2016. To date, only biosimilars for infliximab are available in the…
Abstract Number: 1892 • 2018 ACR/ARHP Annual Meeting
Patient and Health System Characteristics Associated with Receipt of Disease Modifying Anti-Rheumatic Drugs in a National VA Sample
Jennifer Barton^1,2, Aldona Herrndorf³, Gabriela Schmajuk⁴, Rachel A. Matsumoto³, Linda Ganzini^2,3 and Kathleen Carlson^2,3, ¹Rheumatology, VA Portland Health Care System, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³VA Portland Health Care System, Portland, OR, ⁴San Francisco VA Medical Center, San Francisco, CA
Background/Purpose: The Department of Veterans Affairs (VA) operates the largest integrated health care system in the U.S. The proportion of Veterans with RA who receive…
Abstract Number: 1893 • 2018 ACR/ARHP Annual Meeting
Indoleamine-2,3-Dioxygenase in Murine and Human Systemic Lupus Erythematosus
Zev Sthoeger^1,2, Amir Sharabi³, Heidy zinger¹, ilan asher⁴ and edna mozes¹, ¹Department of Immunology, The Weizmann institute of Science, Rehovot, Israel, ²Department of Allergy and Clinical Immunology, Kaplan Medical Center,, Rehovot, Israel, ³Department of Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ⁴Department of Allergy and Clinical Immunology, Kaplan Medical Center, Rehovot, Israel
Background/Purpose: Indoleamine-2,3-dioxygenase (IDO) is a tryptophan catabolizing enzyme which plays a role in immune regulation and in the pathogenesis of autoimmune disorders. Increased IDO activity…
Abstract Number: 1894 • 2018 ACR/ARHP Annual Meeting
Baricitinib-Associated Changes in Type l Interferon Gene Signature during a 24-Week Phase-2 Clinical SLE Trial
Thomas Dörner¹, Yoshiya Tanaka², Michelle Petri³, Josef S. Smolen⁴, Ernst R. Dow⁵, Richard E. Higgs⁵, Robert J. Benschop⁵, Adam Abel⁵, Maria E. Silk⁵, Stephanie de Bono⁵ and Robert W. Hoffman⁵, ¹Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: In the phase 2 study JAHH (NCT02708095), treatment with baricitinib (bari), an oral selective Janus kinase 1/2 inhibitor approved for the treatment of RA,…
Abstract Number: 1895 • 2018 ACR/ARHP Annual Meeting
Marked Immune Cell Subset Changes in Refractory Lupus Patients in a Phase I Trial of Allogenic Mesenchymal Stem Cells
Caroline Wallace Fugle¹, Chungwen Wei², Ignacio Sanz², Zihai Li¹, Chrystal Paulos¹, Megan Wyatt¹, Diane L. Kamen³ and Gary S. Gilkeson⁴, ¹MUSC, Charleston, SC, ²Emory University School of Medicine, Atlanta, GA, ³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁴Department of Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Reports of positive effects of allogenic mesenchymal stem cells (MSCs) in treating refractory lupus, from a single center in China, led us to investigate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].